Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How do you manage a prostate cancer patient with pelvic lymphadenopathy and a single enlarged PSMA PET+ gastrohepatic node?
Do you consider radiation therapy in such a case?
Related Questions
What adjuvant treatment would you offer a patient who underwent cystoprostatectomy for a muscle invasive bladder cancer and discovered to also have prostate cancer?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
What dose-fractionation do you use for salvage HDR brachytherapy for biopsy proven locally recurrent prostate cancer after prior external beam radiotherapy?
How would you manage a patient who developed an intraprostatic abscess after SpaceOAR injection, prior to starting radiation?
How would you treat a patient with isolated CNS relapse of seminoma?
How do you counsel/advise patients when asked to compare ultrahypofractionated radiotherapy with the TULSA procedure?
How do you manage LUTS in the post-prostatectomy setting?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?